Clinical Trial Update: Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.

View source ↗

Summary

The EpiTax study (NCT06550518) reports completion of a real-world evaluation of a second-line epirubicin-paclitaxel regimen for relapsed small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University Hospital, Brest | Conditions: Advanced Small Cell Lung Carcinoma | Status: COMPLETED